Table 4

Clinical-pathological prognostic features of disease
Prevalent (n = 76) vs. Incident screened (n = 65) P value OR
Mean age 56.88 ± 0.65 vs. 59.71 ± 0.68 P < 0.01 0.91 (0.86-0.98)
Mean size (cm) 1.64 ± 0.15 vs. 1.27 ± 0.17 p < 0.05 1.44 (1.01-2.08)
Lymph node positive 25% vs. 21.5% N.S. 1.21 (0.55-2.66)
Poorly-differentiated tumors 32.1% vs. 32.8% N.S. 0.96 (0.49-1.90)
ER positive 87.5% vs. 89.1% N.S. 0.85 (0.27-2.64)
PR positive 70.3% vs. 78.2% N.S. 0.66 (0.28-1.52)
in situ carcinomas 13% vs. 11% N.S. 1.25 (0.44-3.51)
Apoptosis 42.5% vs. 66.7% N.S. 0.37 (0.12-1.11)
Bcl-2 75.4% vs. 81.3% N.S. 0.70 (0.28-1.77)
Ki67 38.5% vs. 63% p < 0.01 0.36 (0.17-0.77)
c-erb-B2 7.4% vs. 23% p < 0.01 0.22 (0.08-0.61)
Delay Diagnosis- treatment (>30 days) 64.5 vs. 35.4 p < 0.01 3.31 (1.65-6.62)

Redondo et al.

Redondo et al. BMC Cancer 2012 12:604   doi:10.1186/1471-2407-12-604

Open Data